Pharmaceutical Technology

JULY 29, 2022

Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. Their platform identifies which regRNAs control the specific gene of interest.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

BioTech 365

OCTOBER 14, 2020

DUBLIN–(BUSINESS WIRE)–The “RNA Therapies in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’s offering.

RNA 40

RNA Business Development Clinical Development Development 40

The Pharma Data

DECEMBER 13, 2020

.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. Both will report to Dr. Dong Wei, CEO of EdiGene.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

pharmaphorum

APRIL 14, 2022

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.

RNA 52

RNA Clinical Trials Clinical Trials Life Science 52

The Pharma Data

DECEMBER 8, 2020

Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases.

RNA 52

RNA Antibody Life Science Protein 52

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Now, we can grow our R&D more rapidly and hire more business development and marketing colleagues to extend our reach to customers,” Del Bourgo says. “This is just the beginning; the potential is enormous,” he says.

Genome 105

Genome Genomics Medicine Development 105

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. In the second quarter of 2021, the company recognized acquired in-process research and development charges of $25.0

Antibody 52

Antibody Sales Development Production 52